All In Biotech

Free tool

FAERS Monitor: Pregnyl

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 017692 or its brand name (Pregnyl, Gonadotropin, Chorionic). Reports on generic versions are filed under their own applications.

Reports

2,092

Serious

1,000

48% of reports

Hospitalization

593

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome520
  • no adverse event226
  • product dose omission issue134
  • drug ineffective115
  • product packaging quantity issue101
  • product quality issue93
  • product use in unapproved indication87
  • inappropriate schedule of drug administration83
  • off label use79
  • ascites76
  • product dose omission73
  • abdominal distension71
  • injection site pain71
  • nausea68
  • headache63

Reports by year received

View as table
YearReports
20042
200510
20066
20075
200810
200913
201011
201118
201245
201339
201473
201548
201666
2017200
2018118
2019160
2020149
2021166
2022258
2023111
2024169
2025112
2026303

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal5202886.32644.31,163,419
product packaging quantity issueSignal10190.774.98,793
ascitesSignal7626.120.91,804
no adverse eventSignal22612.611.12,410
inappropriate schedule of drug administrationSignal8311.79.5807
product dose omissionSignal7311.39.0673
product quality issueSignal936.95.6465
abdominal distensionSignal716.85.4350
product dose omission issueSignal1344.63.9377
product use in unapproved indicationSignal873.52.9157
injection site painSignal712.31.953
headache631.00.80
off label use790.90.71
drug ineffective1150.90.72
nausea680.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.